West Pharmaceutical Services, Inc.
WST
$355.64
$1.530.43%
| 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.56% | 2.18% | 0.60% | -2.14% | 0.09% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.56% | 2.18% | 0.60% | -2.14% | 0.09% |
| Cost of Revenue | 4.49% | 3.95% | 4.67% | 2.38% | 4.15% |
| Gross Profit | -3.03% | -0.55% | -5.39% | -8.68% | -5.67% |
| SG&A Expenses | 11.36% | 12.06% | -20.73% | -7.58% | -12.09% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -29.17% | 46.43% | -94.12% | 45.16% | 17.24% |
| Total Operating Expenses | 5.73% | 5.65% | 0.49% | 1.09% | 1.55% |
| Operating Income | -10.38% | -7.40% | 0.91% | -10.85% | -3.87% |
| Income Before Tax | 2.18% | 2.16% | -9.93% | -21.42% | -14.65% |
| Income Tax Expenses | -1.71% | 6.63% | -2.75% | -3.49% | 17.45% |
| Earnings from Continuing Operations | 3.01% | 1.28% | -11.29% | -24.34% | -19.33% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 3.01% | 1.28% | -11.29% | -24.34% | -19.33% |
| EBIT | -10.38% | -7.40% | 0.91% | -10.85% | -3.87% |
| EBITDA | -6.76% | -4.52% | 1.77% | -9.11% | -3.36% |
| EPS Basic | 3.48% | 1.42% | -11.23% | -24.40% | -19.54% |
| Normalized Basic EPS | -9.07% | -6.40% | 2.47% | -9.29% | -3.29% |
| EPS Diluted | 3.93% | 1.89% | -10.57% | -23.82% | -19.07% |
| Normalized Diluted EPS | -8.69% | -5.99% | 3.05% | -8.70% | -2.66% |
| Average Basic Shares Outstanding | -0.50% | -0.13% | -0.07% | 0.07% | 0.24% |
| Average Diluted Shares Outstanding | -0.92% | -0.56% | -0.63% | -0.59% | -0.43% |
| Dividend Per Share | 5.41% | 5.48% | 5.56% | 5.63% | 5.71% |
| Payout Ratio | 0.02% | 0.04% | 0.19% | 0.41% | 0.31% |
